Latest China News

Synlait Milk has locked in a NZ$320 million refinancing package with a broad banking syndicate and replaced its $130 million shareholder loan, while shifting its financial year-end to December to match its major shareholder.

Sprintex Limited has locked in underwriting agreements covering 8.7 million unexercised options, potentially raising up to A$870,000. The company also agreed to extend a A$1.85 million convertible note maturity by one year, pending shareholder approval.

TruScreen Group posted a NZ$2.25 million loss for FY2026, with its auditor highlighting material uncertainty over the company’s ability to continue without further funding. Revenue rose to NZ$2.4 million amid geographic expansion, but cash burn and accumulated losses remain significant.

Krakatoa Resources has kicked off its 2026 drilling campaign at the Zopkhito Project in Georgia, aiming to convert a significant foreign resource estimate into a JORC-compliant Mineral Resource Estimate while advancing early mine development studies.

TruScreen Group has completed a substantially oversubscribed NZ$2.9 million rights issue, boosting total capital raised to over NZ$4 million. The funds are set to support the company’s global expansion in cervical screening technology.

SDI Limited’s acquisition by Beijing Guoci subsidiary is now effective following New South Wales Supreme Court approval, with the ASX suspension commencing and cash payout scheduled for early July.

The a2 Milk Company has announced a $300 million fully franked special dividend following regulatory clearance in China to rebrand infant formula products under its a2 label.

The Supreme Court of New South Wales has approved the scheme of arrangement for SDI Limited’s acquisition by Beijing Guoci’s subsidiary, paving the way for a cash payout and ASX suspension.

Kingfish Limited posted a $13.6 million net loss for the year ended 31 March 2026, with portfolio returns lagging the benchmark amid geopolitical tensions and AI sector uncertainty.

AFT Pharmaceuticals surged 22% to NZ$254.7 million revenue in FY26, surpassing profit guidance and securing FDA approval to advance a pivotal injectable iron Phase III trial targeting a $7.4 billion market. The company is poised for further global expansion and product launches in FY27.

AFT Pharmaceuticals delivered a 22% revenue jump in FY26 to NZD 254.7 million, surpassing profit guidance and expanding its footprint to 87 countries. The company is advancing multiple R&D projects, including a pivotal Phase III injectable iron trial, while targeting over NZD 300 million in revenue for FY27.

Mount Ridley Mines has confirmed that high-grade scandium mineralisation at its Grass Patch Complex extends beyond the current Block 1 resource in all directions, based on re-assays of 481 historical drill samples. This expansion supports a resource upgrade and highlights the project's strategic importance amid tightening global scandium supply.